TY - JOUR T1 - An automated high-content synaptic phenotyping platform in human neurons and astrocytes reveals a role for BET proteins in synapse assembly JF - bioRxiv DO - 10.1101/2022.05.17.492322 SP - 2022.05.17.492322 AU - Martin H. Berryer AU - Gizem Rizki AU - Sara G. Susco AU - Daisy Lam AU - Angelica Messana AU - Darina Trendafilova AU - Anna Nathanson AU - Kyle W. Karhohs AU - Beth A. Cimini AU - Kathleen Pfaff AU - Anne E. Carpenter AU - Lee L. Rubin AU - Lindy E. Barrett Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/05/17/2022.05.17.492322.abstract N2 - Resolving fundamental molecular and functional processes underlying human synaptic development is crucial for understanding normal brain function as well as dysfunction in disease. Based upon increasing evidence of species divergent features of brain cell types, coupled with emerging studies of complex human disease genetics, we developed the first automated and quantitative high-content synaptic phenotyping platform using human neurons and astrocytes. To establish the robustness of our platform, we screened the effects of 376 small molecules on presynaptic density, neurite outgrowth and cell viability, validating six small molecules which specifically enhanced human presynaptic density in vitro. Astrocytes were essential for mediating the effects of all six small molecules, underscoring the relevance of non-cell autonomous factors in synapse assembly and their importance in synaptic screening applications. Bromodomain and extraterminal (BET) inhibitors emerged as the most prominent hit class and global transcriptional analyses using multiple BET inhibitors confirmed upregulation of synaptic gene expression programs. Through these analyses, we demonstrate the robustness of our automated screening platform for identifying potent synaptic modulators, which can be further leveraged for scaled analyses of human synaptic mechanisms and drug discovery efforts.Competing Interest StatementL.L.R. is a founder of Elevian, Rejuveron, and Vesalius Therapeutics, a member of their scientific advisory boards and a private equity shareholder. All are interested in formulating approaches intended to treat diseases of the nervous system and other tissues. He is also on the advisory board of Alkahest, a Grifols company, focused on the plasma proteome and brain aging. None of these companies provided any financial support for the work in this paper. The remaining authors declare no competing interests. ER -